Bristol Myers Squibb has appointed Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of ...

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

Pharmaceutical companies have been in talks with the U.S. government to figure out how to bring drug prices down after President Trump signed in May an executive order that ties U.S. prices to the ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...